Clinical Takeaway
People with PTSD and co-occurring substance use disorders who use cannabis can still benefit meaningfully from trauma-focused treatments, and cannabis use does not appear to undermine treatment outcomes compared to non-users. Clinicians should not withhold or delay evidence-based trauma-focused care for patients simply because they are using cannabis.
#5 Cannabis use and trauma-focused treatment for co-occurring posttraumatic stress disorder and substance use disorders: A meta-analysis of individual patient data.
Citation: Hill Melanie L et al.. Cannabis use and trauma-focused treatment for co-occurring posttraumatic stress disorder and substance use disorders: A meta-analysis of individual patient data.. Journal of anxiety disorders. 2024. PMID: 38266511.
Design: 6 Journal: 0 N: 4 Recency: 1 Pop: 2 Human: 1 Risk: -2
This meta-analysis directly addresses a critical clinical gap by examining whether standard trauma-focused treatments maintain efficacy in the substantial population of PTSD patients who use cannabis, particularly those with co-occurring substance use disorders—a group often excluded from efficacy trials. The findings provide evidence-based guidance for clinicians managing complex comorbidity, clarifying whether current treatment protocols require modification or whether cannabis use itself represents a barrier to treatment engagement rather than treatment response. Understanding these treatment outcomes is essential for optimizing clinical outcomes in a population with high disability burden and limited treatment options.
Quality Gate Alerts:
- Preclinical only
Abstract: High rates of cannabis use among people with posttraumatic stress disorder (PTSD) have raised questions about the efficacy of evidence-based PTSD treatments for individuals reporting cannabis use, particularly those with co-occurring alcohol or other substance use disorders (SUDs). Using a subset of four randomized clinical trials (RCTs) included in Project Harmony, an individual patient meta-analysis of 36 RCTs (total N = 4046) of treatments for co-occurring PTSD+SUD, we examined differences in trauma-focused (TF) and non-trauma-focused (non-TF) treatment outcomes for individuals who did and did not endorse baseline cannabis use (N = 410; 70% male; 33.2% endorsed cannabis use). Propensity score-weighted mixed effects modeling evaluated main and interactive effects of treatment assignment (TF versus non-TF) and baseline cannabis use (yes/no) on attendance rates and within-treatment changes in PTSD, alcohol, and non-cannabis drug use severity. Results revealed significant improvements across outcomes among participants in all conditions, with larger PTSD symptom reductions but lower attendance among individuals receiving TF versus non-TF treatment in both cannabis groups. Participants achieved similar reductions in alcohol and drug use across all conditions. TF outperformed non-TF treatments regardless of recent cannabis use, underscoring the importance of reducing barriers to accessing TF treatments for individuals reporting cannabis use.
🧠 This meta-analysis addresses a clinically important question about whether cannabis use undermines the effectiveness of trauma-focused PTSD treatment in individuals with co-occurring substance use disorders, drawing from a substantial pool of RCT data. While the pooled sample size is robust, the analysis relies on only four trials specifically examining cannabis use outcomes, which limits the generalizability of findings to the broader cannabis-using PTSD population and may not capture the heterogeneity of cannabis consumption patterns, potency, and frequency that characterize real-world use. The retrospective aggregation of patient-level data also introduces potential confounding from unmeasured variables such as cannabis withdrawal severity, concurrent medication use, and treatment engagement—factors that could plausibly influence both cannabis use trajectories and PTSD symptom response independent of treatment efficacy. Clinicians should interpret these findings as suggestive rather than definitive, recognizing that trauma-focused treatments remain evidence-based for PTSD regardless of cannabis use status, though individualizing treatment intensity